Principal Securities, Inc. Verona Pharma PLC Call Options Transaction History
Principal Securities, Inc.
- $4.47 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VRNA
# of Institutions
290Shares Held
74.3MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$486 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$408 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$290 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$256 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$214 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $4.51B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...